Virtus ETF Advisers LLC Orchard Therapeutics PLC Transaction History

Virtus ETF Advisers LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$1.16 - $2.23 $49,020 - $94,237	-42,259 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$2.24 - $4.29 $4,954 - $9,489	-2,212 Reduced 4.97%	42,259 $97,000
Q2 2021 Aug 10, 2021	SELL	$4.39 - $7.23 $94,543 - $155,705	-21,536 Reduced 32.63%	44,471 $195,000
Q1 2021 May 17, 2021	BUY	$4.39 - $9.08 $5,131 - $10,614	1,169 Added 1.8%	66,007 $479,000
Q4 2020 Feb 12, 2021	BUY	$3.86 - $5.07 $94,747 - $124,448	24,546 Added 60.92%	64,838 $280,000
Q3 2020 Nov 13, 2020	SELL	$4.11 - $6.45 $22,584 - $35,442	-5,495 Reduced 12.0%	40,292 $166,000
Q2 2020 Aug 05, 2020	BUY	$5.75 - $11.99 $95,910 - $199,993	16,680 Added 57.31%	45,787 $275,000
Q1 2020 May 14, 2020	SELL	$5.65 - $15.71 $24,057 - $66,893	-4,258 Reduced 12.76%	29,107 $219,000
Q4 2019 Feb 13, 2020	BUY	$10.15 - $15.58 $162,389 - $249,264	15,999 Added 92.13%	33,365 $459,000
Q3 2019 Nov 12, 2019	SELL	$11.88 - $16.72 $11,487 - $16,168	-967 Reduced 5.27%	17,366 $206,000
Q2 2019 Aug 13, 2019	BUY	$13.2 - $20.63 $241,995 - $378,209	18,333 New	18,333 $256,000

545K

Ticker ORTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,458,000
Description
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's d...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.